Zobrazeno 1 - 10
of 113
pro vyhledávání: ''
Autor:
Daniel L. Flynn, Jarnail Singh, Bryan D. Smith, César Serrano, Alfonso García-Valverde, Anu Gupta
Publikováno v:
Molecular Cancer Therapeutics. 20:1234-1245
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for meta
Autor:
Sung Chul Lim, Youngnam Cho, Y. J. Kim, Seungmin Kang, Kyu Min Kim, Moon-Chang Baek, Keon Wook Kang, Miso Park, Ju Hyun Bae, Sung Baek Jeong, Jin Ki Kim, Dae Won Jun, Yong June Choi, Seung-Hyun Lee, Jiwon Kim, Wankyu Kim, HyungJae Lee, Sung Yun Cho
Publikováno v:
Cancer Research. 81:3539-3553
Extracellular vesicles (EV) in the tumor microenvironment have emerged as crucial mediators that promote proliferation, metastasis, and chemoresistance. However, the role of circulating small EVs (csEV) in cancer progression remains poorly understood
Autor:
Eunice Y. Lau, Man Tong, Katherine Po Sin Chung, Terence K. Lee, Stephanie Ma, Rainbow Wing Hei Leung, Etienne H. Mok, Irene Oi-Lin Ng, Martina Mang Leng Lei, Q Zhao, Vincent W. Keng, Carmen Oi Ning Leung, Hoi Wing Leung, Cong Ma
Publikováno v:
Cancer Research. 81:3229-3240
The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) is a possible way to reverse drug resistance, however, inhibitors that spec
Autor:
Marcos Galán-Ganga, Alberto J. Schuhmacher, Paula Nogales, Fatima Al-Shahrour, Miguel Jiménez-Alcázar, Lucía Zhu, Javier Perales-Patón, Scott W. Lowe, Álvaro Curiel-García, Massimo Squatrito
Publikováno v:
Mol Cancer Ther
Glioblastoma (GBM) is the most frequent and aggressive primary tumor type in the central nervous system in adults. Resistance to chemotherapy remains one of the major obstacles in GBM treatment. Identifying and overcoming the mechanisms of therapy re
Autor:
Samuel Achilefu, Michael H. Ross, Jingyu Xiang, Kristin A. Kwakwa, Elizabeth Cordell, Alison K. Esser, Vivek Sharma, Kristen Pagliai, Francesca Fontana, Jennifer L. Davis, Deborah J. Veis, Suzanne J. Bakewell, Xinming Su, Gregory M. Lanza, Katherine N. Weilbaecher, Gregory C. Fox, Christopher G. Maher, Jothilingam Sivapackiam, James A. J. Fitzpatrick, Yalin Xu, Ha X. Dang, Sheila A. Stewart
Publikováno v:
Mol Cancer Ther
Breast cancer bone metastases are common and incurable. Tumoral integrin β3 (β3) expression is induced through interaction with the bone microenvironment. Although β3 is known to promote bone colonization, its functional role during therapy of est
Autor:
Zhe Zhi, Lei Chen, Yiming Hu, Yongping Shao, Yan Wang, Yibo Ren, Jiankang Liu, Shujun Han, Yuwei Yan, Yan Zheng
Publikováno v:
Cancer Research. 81:2918-2929
The long noncoding RNA (lncRNA) SAMMSON is required for human melanoma cell growth and survival. However, whether SAMMSON regulates the response of mutant BRAF melanoma cells to RAF inhibitors remains unknown. In this work, we showed that SAMMSON is
Autor:
Yueze Liu, Jin Gu, Guangbing Xiong, Zhe Cao, Lei You, Jiangdong Qiu, Wenfang Guan, Gang Yang, Taiping Zhang, Wenbo Guo, Mengyu Feng, Yupei Zhao, Fangyu Zhao, Michael Q. Zhang
Publikováno v:
Clinical Cancer Research. 27:3383-3396
Purpose: Gemcitabine is most commonly used for pancreatic cancer. However, the molecular features and mechanisms of the frequently occurring resistance remain unclear. This work aims at exploring the molecular features of gemcitabine resistance and i
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Takahiro Kodama, Yuta Myojin, Daisuke Motooka, Yu Sato, Ayumu Taguchi, Ryotaro Sakamori, Kazuki Maesaka, Satoshi Tanaka, Tetsuo Takehara, Kazuyoshi Ohkawa, Hayato Hikita, Tomohide Tatsumi, Yoshito Hayashi, Hidetoshi Eguchi, Yuichi Abe, Eiji Mita
Publikováno v:
Clinical Cancer Research. 27:1150-1161
Purpose: Hepatocellular carcinoma (HCC) is characterized by high intertumor heterogeneity of genetic drivers. Two multitarget tyrosine kinase inhibitors (TKI), lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in patients with
Autor:
Michiko Kitamura, Suzanne George, Sandro Santagata, Chiharu Hattori, Toshihiko Doi, Akiko Kawano Nagatsuma, Yuki Abe, Reiko Kamei, Tsuyoshi Karibe, Takuma Iguchi, Jun Hasegawa, Takashi Nakada, Matthew L. Hemming, Koichiro Inaki, Jessica L. Andersen, Amr H. Abdelhamid Ahmed, George D. Demetri, Tomoko Shibutani, Iida Kenji, Toshinori Agatsuma, Taisei Nomura, Satoru Yasuda, Manabu Abe, Atsushi Ochiai
Publikováno v:
Cancer Discovery. 11:1508-1523
Currently, the only approved treatments for gastrointestinal stromal tumor (GIST) are tyrosine kinase inhibitors (TKI), which eventually lead to the development of secondary resistance mutations in KIT or PDGFRA and disease progression. Herein, we id